Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clenbuterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 3/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.60 |
| ▸ | CASP7 | P55210 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clenbuterol SCHEMBL20761507 | 1.00 | ADRB1 (1.00) | ADRB1LMNAADRB2TSHRHTR1A | |
| Clenbuterol SCHEMBL4722 | 1.00 | ADRB1 (1.00) | ADRB1LMNAADRB2TSHRHTR1A | |
| Clenbuterol SCHEMBL123545 | 0.98 | LMNA (1.00) | ADRB1LMNAADRB2TSHRHTR1A | |
| Clenbuterol SCHEMBL28145163 | 0.98 | LMNA (1.00) | ADRB1LMNAADRB2TSHRHTR1A | |
| Clenbuterol SCHEMBL27992618 | 0.97 | ADRB1 (0.94) | ADRB1LMNAADRB2TSHRHTR1A | |
| Clenbuterol SCHEMBL10614465 | 0.93 | LMNA (0.86) | ADRB1LMNAADRB2TSHRHTR1A | |
| SCHEMBL30083793 | 0.90 | ADRB1 (0.81) | ADRB1LMNAADRB2TSHRHTR1A | |
| SCHEMBL10614327 | 0.90 | ADRB1 (0.81) | ADRB1LMNAADRB2TSHRHTR1A | |
| SCHEMBL10657217 | 0.90 | ADRB1 (0.81) | ADRB1LMNAADRB2TSHRHTR1A | |
| Clenbuterol SCHEMBL29483929 | 0.89 | ADRB1 (0.80) | ADRB1LMNAADRB2TSHRHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18704 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031376-A | Keli boron Luo Nami emulsifiable paste and preparation method and application thereof | 南京农业大学 | 2026-05-15 | — | — | CN | claimed |
| US-20260132115-A1 | SUBSTITUTED 3-FLUOROBENZENEPROPANOATE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | TIANJIN GUDUI BIO PHARM CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| EP-4739294-A1 | AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE FOR THE TREATMENT OF ASTHMA | Norton (Waterford) Limited (IE) | 2026-05-13 | — | — | EP | claimed |
| EP-4739295-A1 | AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE FOR THE TREATMENT OF ASTHMA | Norton (Waterford) Limited (IE) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| EP-4434588-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2026-04-08 | — | — | EP | claimed |
| US-20260083698-A1 | Synergistic Stimulation of Mucociliary Clearance to Treat Mucus Obstruction in Cystic Fibrosis and Other Muco-Obstructive Disorders | UNIV LELAND STANFORD JUNIOR (US) | 2026-03-26 | — | — | US | claimed |
| US-12568959-B2 | Organ preservation and/or perfusion solution | XVIVO PERFUSION AB (SE) | 2026-03-10 | — | — | US | claimed |
| US-12558325-B2 | Methods for improving neurological diseases and disorders | CURASEN THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | claimed |
| EP-0298984-A1 | COMPOSITIONS OF LIPOSOMES AND $g(b) 2?-RECEPTOR ACTIVE SUBSTANCES | Aktiebolaget Draco (SE) | 1989-01-18 | — | — | EP | claimed |
| US-4778673-A | THERAPEUTIC OR PROPHYLACTIC ACTION TO PREVENT OR NEUTRALIZE IRRITATION OF RESPIRATORY TRACT MUCOSAE; TERPENES; ODORS | OECE INDUSTRIE CHIMICHE SPA (IT) | 1988-10-18 | — | — | US | claimed |
| EP-0282537-A1 | A NEW SYSTEM FOR ADMINISTRATION OF LIPOSOMES TO MAMMALS | Aktiebolaget Draco (SE) | 1988-09-21 | — | — | EP | claimed |
| WO-1988001862-A1 | A NEW SYSTEM FOR ADMINISTRATION OF LIPOSOMES TO MAMMALS | AKTIEBOLAGET DRACO (SE) | 1988-03-24 | — | — | WO | claimed |
| EP-0260241-A1 | A new system for administration of liposomes to mammals | Aktiebolaget Draco (SE) | 1988-03-16 | — | — | EP | claimed |
| EP-0258356-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR INHALATION. | CHIESI FARMA SPA (IT) | 1988-03-09 | — | — | EP | claimed |
| WO-1987005803-A1 | COMPOSITIONS OF LIPOSOMES AND beta2-RECEPTOR ACTIVE SUBSTANCES | AKTIEBOLAGET DRACO (SE) | 1987-10-08 | — | — | WO | claimed |
| EP-0239798-A1 | New pharmaceutical compositions for inhalation | CHIESI FARMACEUTICI S.p.A. (IT) | 1987-10-07 | — | — | EP | claimed |
| WO-1987005213-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR INHALATION | CHIESI FARMACEUTICI S.P.A. (IT) | 1987-09-11 | — | — | WO | claimed |
| US-4386062-A | Intradermal horse sweat test | RESEARCH CORPORATION (US) | 1983-05-31 | — | — | US | claimed |